What happened
FDA’s records review of Sanrace Biotechnology found significant CGMP violations involving component testing, process control, and quality-unit oversight for OTC drug manufacturing. FDA states the firm did not demonstrate adequate identity testing of incoming components, including an active ingredient, and did not perform the USP identification test capable of detecting specified hazardous impurities on each shipment of each lot. FDA said this left the firm without scientific evidence that components met appropriate specifications before use. The firm’s response also stated that it had no process validation procedures or studies, so it did not demonstrate reproducible, controlled manufacturing yielding uniform quality. FDA further found that the quality unit was not established with adequate responsibility and authority over manufacturing. Cited examples included inadequate laboratory control procedures, an inadequate system monitoring program with insufficient attribute testing, and an inadequate ongoing stability program. Submitted records lacked complete stability data and testing for viscosity, pH, assay, and microbiological attributes throughout shelf life. FDA placed the firm’s drugs on Import Alert 66-40.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, inadequate incoming-component testing may allow unsuitable or hazardous-impurity-contaminated materials to enter production; FDA specifically linked such contamination to lethal poisoning incidents. The absence of process validation weakens evidence that manufacturing is reproducible and remains controlled across its lifecycle. Deficient laboratory monitoring and incomplete stability testing may also limit assurance that finished products meet identity, strength, quality, purity, and shelf-life attributes. Inadequate quality-unit oversight may allow these system-level weaknesses to persist or recur.
Key topics: Missing identity and hazardous-impurity testing for each shipment of each component lot, Absence of process validation procedures and studies, Inadequate quality-unit oversight of laboratory monitoring and stability testing